NCT00362427View on ClinicalTrials.gov

Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®

PHASE2CompletedINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

March 31, 2009

Conditions
DiphtheriaPertussisPolioHepatitis BTetanus
Interventions
BIOLOGICAL

Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC

0.5 mL, 4 doses, IM

BIOLOGICAL

Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC

0.5 Ml, 4 doses, IM

BIOLOGICAL

Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC

0.5 mL, 4 doses, IM with concommitant vaccines

Trial Locations (8)

V3C 4J2

Coquitlam

V3R 8P8

Surrey

R3E 3P4

Winnipeg

B3K 6R8

Halifax

K1S 0G8

Ottawa

G1E 7G9

Beauport

H3H 1P3

Montreal

H3T 1C5

Montreal

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00362427 - Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar® | Biotech Hunter | Biotech Hunter